The Global Tribune

Emovi Announces the Deployment of KneeKG in Europe with Macopharma, a Worldwide Healthcare Leader

 Breaking News
  • No posts were found

Emovi Announces the Deployment of KneeKG in Europe with Macopharma, a Worldwide Healthcare Leader

March 09
07:02 2020
Emovi Announces the Deployment of KneeKG in Europe with Macopharma, a Worldwide Healthcare Leader

Montreal, Quebec – March 9, 2020 – Emovi, Inc., a global medical device company, today announced it has signed an exclusive European distribution agreement with Macopharma for its flagship medical device, KneeKG.

Under the initial four-year agreement, Macopharma will be the exclusive KneeKG distributor in Italy, France, Germany, Poland, Spain, and the UK.

“Knee osteoarthritis (OA) is the most common type of knee pain and is estimated to affect more than 40 million people across Europe,” said Michelle Laflamme, Emovi CEO. “Recent advancement in knee osteoarthritis demonstrates the need to address the dynamic mechanical alignment to identify causes of pain which in turn can reduce pain and improve quality of life.”

Macopharma, as a leader of biosourced biotherapies and with its expertise in blood derivatives, is positioning itself in the OA field. Macopharma, mindful to offer OA treatments to patients, wants to go even further by providing an innovative technology to meet the needs of healthcare professionals in the diagnosis of knee pain in order to help them offer a specific treatment plan for their patients.   

Yvan Malépart, President of Macopharma adds, “After our recent partnership for distribution of a hyaluronic acid (HA) product in the Knee OA market, Emovi was a natural partner for the Macopharma brand. KneeKG is a new level of orthopedic innovation and fits with our strategy as it addresses the causes of pain and function while our HA products tackle pain management.”

KneeKG is the first device that enables doctors to accurately assess patients’ knees in 3D while the patient is moving and weight-bearing. In contrast to static information provided by X-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies the dynamic function of impaired knees allowing healthcare professionals to determine the most strategic treatment plan to restore the knee. By providing doctors with technical information that has a higher correlation to symptoms and at a fraction of the cost of high-tech scans such as MRIs, the KneeKG allows healthcare professionals to significantly improve patients’ quality of life while reducing pain and functional limitations.

Financial terms of the distribution agreement were not disclosed. 

About Emovi Inc.

Headquartered in Montreal, Emovi is a medical device company that develops products for knee joint assessment to restore patient quality of life. In partnership with the Quebec university research community, including the CRCHUM, École de Technologie supérieure (ÉTS), and TELUQ, Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression. Emovi owns multiple patents and the exclusive worldwide license to commercialize KneeKG: https://emovi.ca

About Macopharma

With coverage of over 80 countries, Macopharma is positioned as one of the most influential actors in healthcare. Macopharma is also a worldwide leader in terms of Blood Transfusion Market. They are dedicated to raising the standards of care by relying on closed relationships with their suppliers and users and questioning themselves constantly to become the world’s most trusted healthcare partner.

Media Contact
Company Name: Emovi, Inc.
Contact Person: Dana Summers
Email: Send Email
Phone: 314-659-8430
Address:25 Mozart E. Ave Suite 305
City: Montreal
State: Quebec
Country: Canada
Website: www.emovi.ca